Reports

Industry Research Reports

Home > Reports > Medical Devices & Consumables > Global Spine Biologics Market Research Report 2026

Global Spine Biologics Market Research Report 2026

Global Spine Biologics Market Research Report 2026

Industry: Medical Devices & Consumables

Published Date: 2026-07-11

Pages: 121 Pages

Report ld: 5528373

application for samples

Request Sample

Custom reports

Customized Report

  • Description selected
  • Table of Contents selected
  • Table of Figures selected
  • Related Reports selected
  • PDFPDF Downloadselected
  • Description selected
  • Table of Contents selected
  • Table of Figures selected
  • Related Reports selected
  • PDFPDF Downloadselected

Spine Biologics Market Size(US$)

den_QYR1
cagr

CAGR 2026-2032

6.3%

marketSize

Market Size,2032

USD 3,864

Million

Market Snapshot

Market Size in 2026 (Value)
US$ 2,672 million
Market Forecast in 2032(Value)
US$ 3,864 million
CAGR
6.3%
Years Considered
2021-2032
Base Year
2026
Forecast Period
2026-2032

Source: Secondary research, interviews with experts, and QYResearch analysis

The global Spine Biologics market was valued at US$ 2595 million in 2025 and is anticipated to reach US$ 3864 million by 2032, at a CAGR of 6.3% from 2026 to 2032.

The 2025 U.S. tariff policies introduce profound uncertainty into the global economic landscape. This report critically examines the implications of recent tariff adjustments and international strategic countermeasures on Spine Biologics competitive dynamics, regional economic interdependencies, and supply chain reconfigurations.

Spine Biologics are implantable biological materials and regenerative products used in spinal fusion, bone-defect repair and spinal reconstruction to stimulate new bone formation, improve the local healing environment and increase the probability of successful fusion. Major categories include allograft bone, demineralized bone matrix, cellular bone matrices, synthetic bone-graft substitutes, recombinant bone morphogenetic proteins and collagen-based carrier systems. Depending on their composition, these products may provide an osteoconductive scaffold, osteoinductive biological signals or cells with osteogenic potential. They are generally used together with interbody cages, screws and fixation systems in cervical, thoracic and lumbar procedures for degenerative disease, deformity, trauma, tumor reconstruction and revision surgery. Their principal value is to reduce the additional morbidity associated with harvesting autologous bone while improving fusion predictability in complex or high-risk patients. In 2025, global Spine Biologics production reached approximately 1240 k units.The average gross profit margin of this product is 75%.

Population aging, the increasing burden of degenerative spinal disorders and the growing complexity and personalization of fusion procedures are supporting long-term demand for spine biologics. Compared with reliance on autograft alone, commercial biologic products can reduce donor-site pain and complications while providing additional support for patients with osteoporosis, multilevel fusion, spinal deformity or revision surgery. As navigation, robotics, minimally invasive approaches and advanced interbody devices become more widely adopted, biologics are evolving from supplementary graft materials into critical components influencing fusion quality, procedural efficiency and overall treatment value. The continued expansion of allograft, cellular matrix, synthetic graft and growth-factor portfolios by major spine companies further demonstrates their growing role within integrated spinal-care solutions.

The principal market constraints are clinical-evidence requirements, regulatory complexity and product-safety concerns. Materials differ in osteogenic performance, resorption profile, handling characteristics and patient suitability, making purchasing decisions increasingly dependent on long-term fusion evidence and real-world outcomes. Allograft and cellular products also require rigorous donor screening, infection control, tissue traceability and manufacturing consistency. Regulatory authorities impose strict requirements covering processing, storage and adverse-event management, while historical tissue-transmission events have increased hospital scrutiny of supply-chain safety. Recombinant growth-factor products must be used according to approved indications, dosages and application methods, as concerns regarding off-label use, local inflammatory responses and unwanted bone formation can influence clinical adoption and reimbursement.

Hospital and surgeon purchasing is shifting from selecting a general bone-filling material toward matching the biologic strategy to each patient’s fusion risk. Younger patients undergoing single-level procedures may prioritize affordability and ease of use, while elderly patients, those with poor bone quality and patients requiring multilevel or revision surgery place greater emphasis on biological performance and fusion certainty. Product formats are moving toward injectable, moldable and low-migration designs that can pass through minimally invasive access channels and integrate more closely with interbody-device architecture, surgical approach and digital preoperative planning. Products supported by comprehensive clinical evidence, consistent handling and multiple delivery formats are more likely to enter standardized hospital pathways and generate durable surgeon loyalty and recurring demand.

This report delivers a comprehensive overview of the global Spine Biologics market, with both quantitative and qualitative analyses, to help readers develop growth strategies, assess the competitive landscape, evaluate their position in the current market, and make informed business decisions regarding Spine Biologics. The Spine Biologics market size, estimates, and forecasts are provided in terms of sales volume (K Units) and revenue (US$ millions), with 2025 as the base year and historical and forecast data for 2021–2032.

The report segments the global Spine Biologics market comprehensively. Regional market sizes by Type, by Application, by Spine Procedure, and by company are also provided. For deeper insight, the report profiles the competitive landscape, key competitors, and their respective market rankings, and discusses technological trends and new product developments.

This report will assist Spine Biologics manufacturers, new entrants, and companies across the industry value chain with information on revenues, sales volume, and average prices for the overall market and its sub-segments, by company, by Type, by Application, and by region.

MARKET SEGMENTATION

By Company

  • Medtronic
  • Stryker
  • Johnson & Johnson
  • Zimmer Biomet
  • Orthofix
  • Globus Medical
  • SeaSpine
  • Bioventus
  • Xtant Medical
  • Kuros Biosciences
  • Beijing Chunlizhengda
  • Bonovo Orthopedics

Consumption by Region

  • North America
    • United States
    • Canada
  • Asia-Pacific
    • China
    • Japan
    • South Korea
    • Southeast Asia
    • India
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • U.K.
    • Italy
    • Netherlands
    • Nordic Countries
    • Rest of Europe
  • Latin America
    • Mexico
    • Brazil
    • Rest of Latin America
  • Middle East & Africa
    • Turkey
    • Saudi Arabia
    • UAE
    • Rest of MEA

Segment by Type

  • Bone Graft
  • Bone Graft Substitute
  • Platelet Rich Plasma (PRP)
  • BMAC (Bone Marrow Aspirate Concentrate)

Segment by Application

  • Spinal Fusion
  • Bone Regeneration
  • Orthopedic Reconstruction
  • Minimally Invasive Spine Surgery
  • Other

Segment by Category

  • Lumbar Fusion
  • Cervical Fusion
  • Deformity Correction
  • Revision Spine Surgery
  • Other

Segment by Division

  • Putty
  • Strip
  • Granule
  • Sponge/Collagen Carrier
  • Other

biaoTi CHAPTER OUTLINE

marn_i1

Chapter 1: Defines the scope of the report and presents an executive summary of market segments (by Type, by Application, by Spine Procedure, etc.), including the size of each segment and its future growth potential. It offers a high-level view of the current market and its likely evolution in the short, medium, and long term.

marn_i1

Chapter 2: Provides a detailed analysis of the competitive landscape for Spine Biologics manufacturers, covering pricing, sales and revenue shares, latest development plans, and mergers and acquisitions.

marn_i1

Chapter 3: Examines Spine Biologics sales and revenue at the regional and country levels. It quantifies market size and growth potential for each region and its key countries, and outlines market development, outlook, addressable space, and national market size.

marn_i1

Chapter 4: Analyzes segments by Type, detailing the size and growth potential of each segment to help readers identify “blue ocean” opportunities.

marn_i1

Chapter 5: Analyzes market segments by Application, covering the size and growth potential of each segment to help readers identify “blue ocean” opportunities in downstream markets.

marn_i1

Chapter 6: Profiles key players, presenting core information on leading companies, including product sales, revenue, pricing, gross margin, product portfolio/introductions, and recent developments.

marn_i1

Chapter 7: Reviews the industry value chain, including upstream and downstream segments.

marn_i1

Chapter 8: Discusses market dynamics and recent developments, including drivers, restraints, challenges and risks for manufacturers, U.S. Tariffs and relevant policy analysis.

marn_i1

Chapter 9: Summarizes the key findings and conclusions of the report.

biaoTi QYRESEARCH'S STRENGTHS

Unlike generic global market reports, this study combines macro-level industry trends with hyper-local operational intelligence, empowering data-driven decisions across the Compound Chocolate value chain, addressing:

Market entry risks/opportunities by region
Market entry risks/opportunities by region

We identify regional market threats and growth prospects to guide your overseas layout.

den_ic6
Product mix optimization based on local practices
Product mix optimization based on local practices

We adjust product portfolios in line with local consumption habits.

den_ic6
Competitor tactics in fragmented vs. consolidated markets
Competitor tactics in fragmented vs. consolidated markets

We unpack rivals’ operation strategies for scattered and highly concentrated industries.

den_ic6
Full Research Coverage
Full Research Coverage

We cover competition landscape, full supply chain and quantified market size data, and deliver tailor-made customized surveys to meet your unique business demands.

den_ic6
19 Years Industry Expertise
19 Years Industry Expertise

We own self-owned massive exclusive databases, backed by 19 years of global market research experience across thousands of sectors.

den_ic6
24/7 Fast Report Delivery
24/7 Fast Report Delivery

Our team operates 24 hours a day, 365 days a year, enabling ultra-fast report turnaround to respond to your research needs efficiently.

den_ic6
Localized Strategic Analysis
Localized Strategic Analysis

We integrate regional risk assessment, localized product optimization and competitor analysis to deliver actionable market strategies.

den_ic6
Market entry risks/opportunities by region
Market entry risks/opportunities by region

All data is cross-verified from multiple industry sources to deliver thorough, precise analysis that supports reliable corporate strategic decisions.

den_ic6
Market entry risks/opportunities by region
Market entry risks/opportunities by region

We provide responsive, dedicated after-sales support to resolve all follow-up inquiries about reports, data and industry interpretation.

den_ic6
den_biaoTiZhungShi

TABLE OF CONTENTS

muLu

1 Spine Biologics Market Overview

1.1 Product Definition

1.2 Spine Biologics by Type

1.2.1 Global Spine Biologics Market Value by Type: 2025 vs 2032

1.2.2 Bone Graft

1.2.3 Bone Graft Substitute

1.2.4 Platelet Rich Plasma (PRP)

1.2.5 BMAC (Bone Marrow Aspirate Concentrate)

1.3 Spine Biologics by Spine Procedure

1.3.1 Global Spine Biologics Market Value by Spine Procedure: 2025 vs 2032

1.3.2 Lumbar Fusion

1.3.3 Cervical Fusion

1.3.4 Deformity Correction

1.3.5 Revision Spine Surgery

1.3.6 Other

1.4 Spine Biologics by Product Form

1.4.1 Global Spine Biologics Market Value by Product Form: 2025 vs 2032

1.4.2 Putty

1.4.3 Strip

1.4.4 Granule

1.4.5 Sponge/Collagen Carrier

1.4.6 Other

1.5 Spine Biologics by Application

1.5.1 Global Spine Biologics Market Value by Application: 2025 vs 2032

1.5.2 Spinal Fusion

1.5.3 Bone Regeneration

1.5.4 Orthopedic Reconstruction

1.5.5 Minimally Invasive Spine Surgery

1.5.6 Other

1.6 Global Spine Biologics Market Size Estimates and Forecasts

1.6.1 Global Spine Biologics Revenue 2021–2032

1.6.2 Global Spine Biologics Sales 2021–2032

1.6.3 Global Spine Biologics Market Average Price (2021–2032)

1.7 Assumptions and Limitations

muLu

2 Spine Biologics Market Competition by Manufacturers

2.1 Global Spine Biologics Sales Market Share by Manufacturers (2021–2026)

2.2 Global Spine Biologics Revenue Market Share by Manufacturers (2021–2026)

2.3 Global Spine Biologics Average Price by Manufacturers (2021–2026)

2.4 Global Key Players of Spine Biologics, Industry Ranking, 2023 vs 2024 vs 2025

2.5 Global Key Manufacturers of Spine Biologics, Manufacturing Sites and Headquarters

2.6 Global Key Manufacturers of Spine Biologics, Product Types and Applications

2.7 Global Key Manufacturers of Spine Biologics, Date of Entry into the Industry

2.8 Global Spine Biologics Market Competitive Situation and Trends

2.8.1 Global Spine Biologics Market Concentration Rate

2.8.2 The Top 5 and Top 10 Global Spine Biologics Players Market Share by Revenue

2.8.3 Global Spine Biologics Market Share by Company Tier (Tier 1, Tier 2, Tier 3)

2.9 Manufacturers Mergers & Acquisitions, Expansion Plans

muLu

3 Global Spine Biologics Market Scenario by Region

3.1 Global Spine Biologics Market Size by Region: 2021 vs 2025 vs 2032

3.2 Global Spine Biologics Sales by Region: 2021–2032

3.2.1 Global Spine Biologics Sales by Region: 2021–2026

3.2.2 Global Spine Biologics Sales by Region: 2027–2032

3.3 Global Spine Biologics Revenue by Region: 2021–2032

3.3.1 Global Spine Biologics Revenue by Region: 2021–2026

3.3.2 Global Spine Biologics Revenue by Region: 2027–2032

3.4 North America Spine Biologics Market Facts & Figures by Country

3.4.1 North America Spine Biologics Market Size by Country: 2021 vs 2025 vs 2032

3.4.2 North America Spine Biologics Sales by Country (2021–2032)

3.4.3 North America Spine Biologics Revenue by Country (2021–2032)

3.4.4 U.S.

3.4.5 Canada

3.5 Europe Spine Biologics Market Facts & Figures by Country

3.5.1 Europe Spine Biologics Market Size by Country: 2021 vs 2025 vs 2032

3.5.2 Europe Spine Biologics Sales by Country (2021–2032)

3.5.3 Europe Spine Biologics Revenue by Country (2021–2032)

3.5.4 Germany

3.5.5 France

3.5.6 U.K.

3.5.7 Italy

3.5.8 Russia

3.6 Asia Pacific Spine Biologics Market Facts & Figures by Region

3.6.1 Asia Pacific Spine Biologics Market Size by Region: 2021 vs 2025 vs 2032

3.6.2 Asia Pacific Spine Biologics Sales by Region (2021–2032)

3.6.3 Asia Pacific Spine Biologics Revenue by Region (2021–2032)

3.6.4 China

3.6.5 Japan

3.6.6 South Korea

3.6.7 India

3.6.8 Australia

3.6.9 China Taiwan

3.6.10 Indonesia

3.6.11 Thailand

3.6.12 Malaysia

3.7 Latin America Spine Biologics Market Facts & Figures by Country

3.7.1 Latin America Spine Biologics Market Size by Country: 2021 vs 2025 vs 2032

3.7.2 Latin America Spine Biologics Sales by Country (2021–2032)

3.7.3 Latin America Spine Biologics Revenue by Country (2021–2032)

3.7.4 Mexico

3.7.5 Brazil

3.7.6 Argentina

3.8 Middle East and Africa Spine Biologics Market Facts & Figures by Country

3.8.1 Middle East and Africa Spine Biologics Market Size by Country: 2021 vs 2025 vs 2032

3.8.2 Middle East and Africa Spine Biologics Sales by Country (2021–2032)

3.8.3 Middle East and Africa Spine Biologics Revenue by Country (2021–2032)

3.8.4 Turkey

3.8.5 Saudi Arabia

3.8.6 UAE

muLu

4 Segment by Type

4.1 Global Spine Biologics Sales by Type (2021–2032)

4.1.1 Global Spine Biologics Sales by Type (2021–2026)

4.1.2 Global Spine Biologics Sales by Type (2027–2032)

4.1.3 Global Spine Biologics Sales Market Share by Type (2021–2032)

4.2 Global Spine Biologics Revenue by Type (2021–2032)

4.2.1 Global Spine Biologics Revenue by Type (2021–2026)

4.2.2 Global Spine Biologics Revenue by Type (2027–2032)

4.2.3 Global Spine Biologics Revenue Market Share by Type (2021–2032)

4.3 Global Spine Biologics Price by Type (2021–2032)

muLu

5 Segment by Application

5.1 Global Spine Biologics Sales by Application (2021–2032)

5.1.1 Global Spine Biologics Sales by Application (2021–2026)

5.1.2 Global Spine Biologics Sales by Application (2027–2032)

5.1.3 Global Spine Biologics Sales Market Share by Application (2021–2032)

5.2 Global Spine Biologics Revenue by Application (2021–2032)

5.2.1 Global Spine Biologics Revenue by Application (2021–2026)

5.2.2 Global Spine Biologics Revenue by Application (2027–2032)

5.2.3 Global Spine Biologics Revenue Market Share by Application (2021–2032)

5.3 Global Spine Biologics Price by Application (2021–2032)

muLu

6 Key Companies Profiled

6.1 Medtronic

6.1.1 Medtronic Company Information

6.1.2 Medtronic Description and Business Overview

6.1.3 Medtronic Spine Biologics Sales, Revenue, and Gross Margin (2021–2026)

6.1.4 Medtronic Spine Biologics Product Portfolio

6.1.5 Medtronic Recent Developments/Updates

6.2 Stryker

6.2.1 Stryker Company Information

6.2.2 Stryker Description and Business Overview

6.2.3 Stryker Spine Biologics Sales, Revenue, and Gross Margin (2021–2026)

6.2.4 Stryker Spine Biologics Product Portfolio

6.2.5 Stryker Recent Developments/Updates

6.3 Johnson & Johnson

6.3.1 Johnson & Johnson Company Information

6.3.2 Johnson & Johnson Description and Business Overview

6.3.3 Johnson & Johnson Spine Biologics Sales, Revenue, and Gross Margin (2021–2026)

6.3.4 Johnson & Johnson Spine Biologics Product Portfolio

6.3.5 Johnson & Johnson Recent Developments/Updates

6.4 Zimmer Biomet

6.4.1 Zimmer Biomet Company Information

6.4.2 Zimmer Biomet Description and Business Overview

6.4.3 Zimmer Biomet Spine Biologics Sales, Revenue, and Gross Margin (2021–2026)

6.4.4 Zimmer Biomet Spine Biologics Product Portfolio

6.4.5 Zimmer Biomet Recent Developments/Updates

6.5 Orthofix

6.5.1 Orthofix Company Information

6.5.2 Orthofix Description and Business Overview

6.5.3 Orthofix Spine Biologics Sales, Revenue, and Gross Margin (2021–2026)

6.5.4 Orthofix Spine Biologics Product Portfolio

6.5.5 Orthofix Recent Developments/Updates

6.6 Globus Medical

6.6.1 Globus Medical Company Information

6.6.2 Globus Medical Description and Business Overview

6.6.3 Globus Medical Spine Biologics Sales, Revenue, and Gross Margin (2021–2026)

6.6.4 Globus Medical Spine Biologics Product Portfolio

6.6.5 Globus Medical Recent Developments/Updates

6.7 SeaSpine

6.7.1 SeaSpine Company Information

6.7.2 SeaSpine Description and Business Overview

6.7.3 SeaSpine Spine Biologics Sales, Revenue, and Gross Margin (2021–2026)

6.7.4 SeaSpine Spine Biologics Product Portfolio

6.7.5 SeaSpine Recent Developments/Updates

6.8 Bioventus

6.8.1 Bioventus Company Information

6.8.2 Bioventus Description and Business Overview

6.8.3 Bioventus Spine Biologics Sales, Revenue, and Gross Margin (2021–2026)

6.8.4 Bioventus Spine Biologics Product Portfolio

6.8.5 Bioventus Recent Developments/Updates

6.9 Xtant Medical

6.9.1 Xtant Medical Company Information

6.9.2 Xtant Medical Description and Business Overview

6.9.3 Xtant Medical Spine Biologics Sales, Revenue, and Gross Margin (2021–2026)

6.9.4 Xtant Medical Spine Biologics Product Portfolio

6.9.5 Xtant Medical Recent Developments/Updates

6.10 Kuros Biosciences

6.10.1 Kuros Biosciences Company Information

6.10.2 Kuros Biosciences Description and Business Overview

6.10.3 Kuros Biosciences Spine Biologics Sales, Revenue, and Gross Margin (2021–2026)

6.10.4 Kuros Biosciences Spine Biologics Product Portfolio

6.10.5 Kuros Biosciences Recent Developments/Updates

6.11 Beijing Chunlizhengda

6.11.1 Beijing Chunlizhengda Company Information

6.11.2 Beijing Chunlizhengda Description and Business Overview

6.11.3 Beijing Chunlizhengda Spine Biologics Sales, Revenue, and Gross Margin (2021–2026)

6.11.4 Beijing Chunlizhengda Spine Biologics Product Portfolio

6.11.5 Beijing Chunlizhengda Recent Developments/Updates

6.12 Bonovo Orthopedics

6.12.1 Bonovo Orthopedics Company Information

6.12.2 Bonovo Orthopedics Description and Business Overview

6.12.3 Bonovo Orthopedics Spine Biologics Sales, Revenue, and Gross Margin (2021–2026)

6.12.4 Bonovo Orthopedics Spine Biologics Product Portfolio

6.12.5 Bonovo Orthopedics Recent Developments/Updates

muLu

7 Industry Chain and Sales Channels Analysis

7.1 Spine Biologics Industry Chain Analysis

7.2 Spine Biologics Raw Material Supply Analysis

7.2.1 Key Raw Materials

7.2.2 Raw Materials Key Suppliers

7.3 Spine Biologics Production Mode & Process Analysis

7.4 Spine Biologics Sales and Marketing

7.4.1 Spine Biologics Sales Channels

7.4.2 Spine Biologics Distributors

7.5 Spine Biologics Customer Analysis

muLu

8 Spine Biologics Market Dynamics

8.1 Spine Biologics Industry Trends

8.2 Spine Biologics Market Drivers

8.3 Spine Biologics Market Challenges

8.4 Spine Biologics Market Restraints

8.5 Impact of U.S. Tariffs

muLu

9 Research Findings and Conclusion

muLu

10 Methodology and Data Source

10.1 Methodology/Research Approach

10.1.1 Research Programs/Design

10.1.2 Market Size Estimation

10.1.3 Market Breakdown and Data Triangulation

10.2 Data Source

10.2.1 Secondary Sources

10.2.2 Primary Sources

10.3 Author List

10.4 Disclaimer

den_biaoTiZhungShi

TABLE OF FIGURES

muLu

List of Tables

Table 1. Global Spine Biologics Market Value by Type (US$ Million), 2025 vs 2032
Table 2. Global Spine Biologics Market Value by Spine Procedure (US$ Million), 2025 vs 2032
Table 3. Global Spine Biologics Market Value by Product Form (US$ Million), 2025 vs 2032
Table 4. Global Spine Biologics Market Value by Application (US$ Million), 2025 vs 2032
Table 5. Global Spine Biologics Market Competitive Situation by Manufacturers in 2025
Table 6. Global Spine Biologics Sales (K Units) of Key Manufacturers (2021–2026)
Table 7. Global Spine Biologics Sales Market Share by Manufacturers (2021–2026)
Table 8. Global Spine Biologics Revenue (US$ Million) by Manufacturers (2021–2026)
Table 9. Global Spine Biologics Revenue Share by Manufacturers (2021–2026)
Table 10. Global Market Spine Biologics Average Price (USD/Unit) of Key Manufacturers (2021–2026)
Table 11. Global Key Players of Spine Biologics, Industry Ranking, 2023 vs 2024 vs 2025
Table 12. Global Key Manufacturers of Spine Biologics, Manufacturing Sites and Headquarters
Table 13. Global Key Manufacturers of Spine Biologics, Product Types and Applications
Table 14. Global Key Manufacturers of Spine Biologics, Date of Entry into the Industry
Table 15. Global Manufacturers Market Concentration Ratio (CR5 and HHI)
Table 16. Global Spine Biologics Companies by Tier (Tier 1, Tier 2, Tier 3), based on Spine Biologics Revenue, 2025
Table 17. Manufacturers Mergers & Acquisitions, Expansion Plans
Table 18. Global Spine Biologics Market Size by Region (US$ Million): 2021 vs 2025 vs 2032
Table 19. Global Spine Biologics Sales by Region (K Units), 2021–2026
Table 20. Global Spine Biologics Sales Market Share by Region (2021–2026)
Table 21. Global Spine Biologics Sales by Region (K Units), 2027–2032
Table 22. Global Spine Biologics Sales Market Share by Region (2027–2032)
Table 23. Global Spine Biologics Revenue by Region (US$ Million), 2021–2026
Table 24. Global Spine Biologics Revenue Market Share by Region (2021–2026)
Table 25. Global Spine Biologics Revenue by Region (US$ Million), 2027–2032
Table 26. Global Spine Biologics Revenue Market Share by Region (2027–2032)
Table 27. North America Spine Biologics Revenue by Country: 2021 vs 2025 vs 2032 (US$ Million)
Table 28. North America Spine Biologics Sales by Country (K Units), 2021–2026
Table 29. North America Spine Biologics Sales by Country (K Units), 2027–2032
Table 30. North America Spine Biologics Revenue by Country (US$ Million), 2021–2026
Table 31. North America Spine Biologics Revenue by Country (US$ Million), 2027–2032
Table 32. Europe Spine Biologics Revenue by Country: 2021 vs 2025 vs 2032 (US$ Million)
Table 33. Europe Spine Biologics Sales by Country (K Units), 2021–2026
Table 34. Europe Spine Biologics Sales by Country (K Units), 2027–2032
Table 35. Europe Spine Biologics Revenue by Country (US$ Million), 2021–2026
Table 36. Europe Spine Biologics Revenue by Country (US$ Million), 2027–2032
Table 37. Asia Pacific Spine Biologics Revenue by Region: 2021 vs 2025 vs 2032 (US$ Million)
Table 38. Asia Pacific Spine Biologics Sales by Region (K Units), 2021–2026
Table 39. Asia Pacific Spine Biologics Sales by Region (K Units), 2027–2032
Table 40. Asia Pacific Spine Biologics Revenue by Region (US$ Million), 2021–2026
Table 41. Asia Pacific Spine Biologics Revenue by Region (US$ Million), 2027–2032
Table 42. Latin America Spine Biologics Revenue by Country: 2021 vs 2025 vs 2032 (US$ Million)
Table 43. Latin America Spine Biologics Sales by Country (K Units), 2021–2026
Table 44. Latin America Spine Biologics Sales by Country (K Units), 2027–2032
Table 45. Latin America Spine Biologics Revenue by Country (US$ Million), 2021–2026
Table 46. Latin America Spine Biologics Revenue by Country (US$ Million), 2027–2032
Table 47. Middle East and Africa Spine Biologics Revenue by Country: 2021 vs 2025 vs 2032 (US$ Million)
Table 48. Middle East and Africa Spine Biologics Sales by Country (K Units), 2021–2026
Table 49. Middle East and Africa Spine Biologics Sales by Country (K Units), 2027–2032
Table 50. Middle East and Africa Spine Biologics Revenue by Country (US$ Million), 2021–2026
Table 51. Middle East and Africa Spine Biologics Revenue by Country (US$ Million), 2027–2032
Table 52. Global Spine Biologics Sales (K Units) by Type (2021–2026)
Table 53. Global Spine Biologics Sales (K Units) by Type (2027–2032)
Table 54. Global Spine Biologics Sales Market Share by Type (2021–2026)
Table 55. Global Spine Biologics Sales Market Share by Type (2027–2032)
Table 56. Global Spine Biologics Revenue (US$ Million) by Type (2021–2026)
Table 57. Global Spine Biologics Revenue (US$ Million) by Type (2027–2032)
Table 58. Global Spine Biologics Revenue Market Share by Type (2021–2026)
Table 59. Global Spine Biologics Revenue Market Share by Type (2027–2032)
Table 60. Global Spine Biologics Price (USD/Unit) by Type (2021–2026)
Table 61. Global Spine Biologics Price (USD/Unit) by Type (2027–2032)
Table 62. Global Spine Biologics Sales (K Units) by Application (2021–2026)
Table 63. Global Spine Biologics Sales (K Units) by Application (2027–2032)
Table 64. Global Spine Biologics Sales Market Share by Application (2021–2026)
Table 65. Global Spine Biologics Sales Market Share by Application (2027–2032)
Table 66. Global Spine Biologics Revenue (US$ Million) by Application (2021–2026)
Table 67. Global Spine Biologics Revenue (US$ Million) by Application (2027–2032)
Table 68. Global Spine Biologics Revenue Market Share by Application (2021–2026)
Table 69. Global Spine Biologics Revenue Market Share by Application (2027–2032)
Table 70. Global Spine Biologics Price (USD/Unit) by Application (2021–2026)
Table 71. Global Spine Biologics Price (USD/Unit) by Application (2027–2032)
Table 72. Medtronic Company Information
Table 73. Medtronic Description and Business Overview
Table 74. Medtronic Spine Biologics Sales (K Units), Revenue (US$ Million), Price (USD/Unit), and Gross Margin (2021–2026)
Table 75. Medtronic Spine Biologics Product
Table 76. Medtronic Recent Developments/Updates
Table 77. Stryker Company Information
Table 78. Stryker Description and Business Overview
Table 79. Stryker Spine Biologics Sales (K Units), Revenue (US$ Million), Price (USD/Unit), and Gross Margin (2021–2026)
Table 80. Stryker Spine Biologics Product
Table 81. Stryker Recent Developments/Updates
Table 82. Johnson & Johnson Company Information
Table 83. Johnson & Johnson Description and Business Overview
Table 84. Johnson & Johnson Spine Biologics Sales (K Units), Revenue (US$ Million), Price (USD/Unit), and Gross Margin (2021–2026)
Table 85. Johnson & Johnson Spine Biologics Product
Table 86. Johnson & Johnson Recent Developments/Updates
Table 87. Zimmer Biomet Company Information
Table 88. Zimmer Biomet Description and Business Overview
Table 89. Zimmer Biomet Spine Biologics Sales (K Units), Revenue (US$ Million), Price (USD/Unit), and Gross Margin (2021–2026)
Table 90. Zimmer Biomet Spine Biologics Product
Table 91. Zimmer Biomet Recent Developments/Updates
Table 92. Orthofix Company Information
Table 93. Orthofix Description and Business Overview
Table 94. Orthofix Spine Biologics Sales (K Units), Revenue (US$ Million), Price (USD/Unit), and Gross Margin (2021–2026)
Table 95. Orthofix Spine Biologics Product
Table 96. Orthofix Recent Developments/Updates
Table 97. Globus Medical Company Information
Table 98. Globus Medical Description and Business Overview
Table 99. Globus Medical Spine Biologics Sales (K Units), Revenue (US$ Million), Price (USD/Unit), and Gross Margin (2021–2026)
Table 100. Globus Medical Spine Biologics Product
Table 101. Globus Medical Recent Developments/Updates
Table 102. SeaSpine Company Information
Table 103. SeaSpine Description and Business Overview
Table 104. SeaSpine Spine Biologics Sales (K Units), Revenue (US$ Million), Price (USD/Unit), and Gross Margin (2021–2026)
Table 105. SeaSpine Spine Biologics Product
Table 106. SeaSpine Recent Developments/Updates
Table 107. Bioventus Company Information
Table 108. Bioventus Description and Business Overview
Table 109. Bioventus Spine Biologics Sales (K Units), Revenue (US$ Million), Price (USD/Unit), and Gross Margin (2021–2026)
Table 110. Bioventus Spine Biologics Product
Table 111. Bioventus Recent Developments/Updates
Table 112. Xtant Medical Company Information
Table 113. Xtant Medical Description and Business Overview
Table 114. Xtant Medical Spine Biologics Sales (K Units), Revenue (US$ Million), Price (USD/Unit), and Gross Margin (2021–2026)
Table 115. Xtant Medical Spine Biologics Product
Table 116. Xtant Medical Recent Developments/Updates
Table 117. Kuros Biosciences Company Information
Table 118. Kuros Biosciences Description and Business Overview
Table 119. Kuros Biosciences Spine Biologics Sales (K Units), Revenue (US$ Million), Price (USD/Unit), and Gross Margin (2021–2026)
Table 120. Kuros Biosciences Spine Biologics Product
Table 121. Kuros Biosciences Recent Developments/Updates
Table 122. Beijing Chunlizhengda Company Information
Table 123. Beijing Chunlizhengda Description and Business Overview
Table 124. Beijing Chunlizhengda Spine Biologics Sales (K Units), Revenue (US$ Million), Price (USD/Unit), and Gross Margin (2021–2026)
Table 125. Beijing Chunlizhengda Spine Biologics Product
Table 126. Beijing Chunlizhengda Recent Developments/Updates
Table 127. Bonovo Orthopedics Company Information
Table 128. Bonovo Orthopedics Description and Business Overview
Table 129. Bonovo Orthopedics Spine Biologics Sales (K Units), Revenue (US$ Million), Price (USD/Unit), and Gross Margin (2021–2026)
Table 130. Bonovo Orthopedics Spine Biologics Product
Table 131. Bonovo Orthopedics Recent Developments/Updates
Table 132. Key Raw Materials Lists
Table 133. Raw Materials Key Suppliers Lists
Table 134. Spine Biologics Distributors List
Table 135. Spine Biologics Customers List
Table 136. Spine Biologics Market Trends
Table 137. Spine Biologics Market Drivers
Table 138. Spine Biologics Market Challenges
Table 139. Spine Biologics Market Restraints
Table 140. Research Programs/Design for This Report
Table 141. Key Data Information from Secondary Sources
Table 142. Key Data Information from Primary Sources
Table 143. Authors List of This Report
muLu

List of Figures

Figure 1. Product Picture of Spine Biologics
Figure 2. Global Spine Biologics Market Value by Type (US$ Million), 2021–2032
Figure 3. Global Spine Biologics Market Share by Type: 2025 & 2032
Figure 4. Bone Graft Product Picture
Figure 5. Bone Graft Substitute Product Picture
Figure 6. Platelet Rich Plasma (PRP) Product Picture
Figure 7. BMAC (Bone Marrow Aspirate Concentrate) Product Picture
Figure 8. Global Spine Biologics Market Value by Spine Procedure (US$ Million), 2021–2032
Figure 9. Global Spine Biologics Market Share by Spine Procedure: 2025 vs 2032
Figure 10. Lumbar Fusion Product Picture
Figure 11. Cervical Fusion Product Picture
Figure 12. Deformity Correction Product Picture
Figure 13. Revision Spine Surgery Product Picture
Figure 14. Other Product Picture
Figure 15. Global Spine Biologics Market Value by Product Form (US$ Million), 2021–2032
Figure 16. Global Spine Biologics Market Share by Product Form: 2025 vs 2032
Figure 17. Putty Product Picture
Figure 18. Strip Product Picture
Figure 19. Granule Product Picture
Figure 20. Sponge/Collagen Carrier Product Picture
Figure 21. Other Product Picture
Figure 22. Global Spine Biologics Market Value by Application (US$ Million), 2021–2032
Figure 23. Global Spine Biologics Market Share by Application: 2025 & 2032
Figure 24. Spinal Fusion
Figure 25. Bone Regeneration
Figure 26. Orthopedic Reconstruction
Figure 27. Minimally Invasive Spine Surgery
Figure 28. Other
Figure 29. Global Spine Biologics Revenue, (US$ Million), 2021 vs 2025 vs 2032
Figure 30. Global Spine Biologics Market Size (US$ Million), 2021–2032
Figure 31. Global Spine Biologics Sales (K Units), 2021–2032
Figure 32. Global Spine Biologics Average Price (USD/Unit), 2021–2032
Figure 33. Spine Biologics Report Years Considered
Figure 34. Spine Biologics Sales Share by Manufacturers in 2025
Figure 35. Global Spine Biologics Revenue Share by Manufacturers in 2025
Figure 36. Top 5 and Top 10 Global Spine Biologics Players: Market Share by Revenue in Spine Biologics in 2025
Figure 37. Spine Biologics Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2021 vs 2025
Figure 38. Global Spine Biologics Market Size by Region (US$ Million): 2021 vs 2025 vs 2032
Figure 39. North America Spine Biologics Sales Market Share by Country (2021–2032)
Figure 40. North America Spine Biologics Revenue Market Share by Country (2021–2032)
Figure 41. U.S. Spine Biologics Revenue Growth Rate (US$ Million), 2021–2032
Figure 42. Canada Spine Biologics Revenue Growth Rate (US$ Million), 2021–2032
Figure 43. Europe Spine Biologics Sales Market Share by Country (2021–2032)
Figure 44. Europe Spine Biologics Revenue Market Share by Country (2021–2032)
Figure 45. Germany Spine Biologics Revenue Growth Rate (US$ Million), 2021–2032
Figure 46. France Spine Biologics Revenue Growth Rate (US$ Million), 2021–2032
Figure 47. U.K. Spine Biologics Revenue Growth Rate (US$ Million), 2021–2032
Figure 48. Italy Spine Biologics Revenue Growth Rate (US$ Million), 2021–2032
Figure 49. Russia Spine Biologics Revenue Growth Rate (US$ Million), 2021–2032
Figure 50. Asia Pacific Spine Biologics Sales Market Share by Region (2021–2032)
Figure 51. Asia Pacific Spine Biologics Revenue Market Share by Region (2021–2032)
Figure 52. China Spine Biologics Revenue Growth Rate (US$ Million), 2021–2032
Figure 53. Japan Spine Biologics Revenue Growth Rate (US$ Million), 2021–2032
Figure 54. South Korea Spine Biologics Revenue Growth Rate (US$ Million), 2021–2032
Figure 55. India Spine Biologics Revenue Growth Rate (US$ Million), 2021–2032
Figure 56. Australia Spine Biologics Revenue Growth Rate (US$ Million), 2021–2032
Figure 57. China Taiwan Spine Biologics Revenue Growth Rate (US$ Million), 2021–2032
Figure 58. Indonesia Spine Biologics Revenue Growth Rate (US$ Million), 2021–2032
Figure 59. Thailand Spine Biologics Revenue Growth Rate (US$ Million), 2021–2032
Figure 60. Malaysia Spine Biologics Revenue Growth Rate (US$ Million), 2021–2032
Figure 61. Latin America Spine Biologics Sales Market Share by Country (2021–2032)
Figure 62. Latin America Spine Biologics Revenue Market Share by Country (2021–2032)
Figure 63. Mexico Spine Biologics Revenue Growth Rate (US$ Million), 2021–2032
Figure 64. Brazil Spine Biologics Revenue Growth Rate (US$ Million), 2021–2032
Figure 65. Argentina Spine Biologics Revenue Growth Rate (US$ Million), 2021–2032
Figure 66. Middle East and Africa Spine Biologics Sales Market Share by Country (2021–2032)
Figure 67. Middle East and Africa Spine Biologics Revenue Market Share by Country (2021–2032)
Figure 68. Turkey Spine Biologics Revenue Growth Rate (US$ Million), 2021–2032
Figure 69. Saudi Arabia Spine Biologics Revenue Growth Rate (US$ Million), 2021–2032
Figure 70. UAE Spine Biologics Revenue Growth Rate (US$ Million), 2021–2032
Figure 71. Global Sales Market Share of Spine Biologics by Type (2021–2032)
Figure 72. Global Revenue Market Share of Spine Biologics by Type (2021–2032)
Figure 73. Global Spine Biologics Price (USD/Unit) by Type (2021–2032)
Figure 74. Global Sales Market Share of Spine Biologics by Application (2021–2032)
Figure 75. Global Revenue Market Share of Spine Biologics by Application (2021–2032)
Figure 76. Global Spine Biologics Price (USD/Unit) by Application (2021–2032)
Figure 77. Spine Biologics Value Chain
Figure 78. Channels of Distribution (Direct Vs Distribution)
Figure 79. Bottom-up and Top-down Approaches for This Report
Figure 80. Data Triangulation
Figure 81. Key Executives Interviewed
den_biaoTiZhungShi

KEY QUESTIONS ADDRESSED BY THE REPORT

Which companies rank high in the global Spine Biologics market?zhanKai
The top companies in the global Spine Biologics market are Medtronic、Stryker、Johnson & Johnson.
What is the annual compound growth rate of the global Spine Biologics market size from 2026 to 2032?shouQi
Which region is expected to have the highest market share?shouQi
What was the global market size of Spine Biologics in 2032?shouQi
What was the global market size of Spine Biologics in 2026?shouQi
den_biaoTiZhungShi

Related Reports

Global Spine Biologics Market Research Report 2026

Industry: Medical Devices & Consumables

Published Date: 2026-07-11

Pages: 121 Pages

Report ld: 5528373

CHOOSE LICENSE TYPE
tip

USD 2900.00

tip

USD 4350.00

tip

USD 5800.00

Add to Cart

Add to Cart

Buy Now

Buy Now

HAVE A QUESTION?
SIMON LEE

SIMON LEE

+1-62 6295 2442

English,Chinese

Offline

HITESH

HITESH

+91-86 6998 6909

English, Hindi

Offline

TANG XIN

TANG XIN

+81-90 3800 9273

Japanese,English

Offline

SUNG-BIN YOON

SUNG-BIN YOON

+82-2883 1278

Korean, English

Offline

YUJIE TIAN

YUJIE TIAN

+86-135-2215-3954

Chinese, English

Offline

DAMON

DAMON

+86-133 1872 9947

Chinese, English

Offline

General Email:
global@qyresearch.com

REPORT COVERAGE

den_ic8

DESCRIPTION

zhankai
den_ic7

OVERVIEW

den_ic7

MARKET SEGMENTATION

den_ic7

CHAPTER OUTLINE

den_ic7

QYRESEARCH'S STRENGTHS

den_ic8

TABLE OF CONTENTS

den_ic8

TABLE OF FIGURES

den_ic8

RLEATED REPORTS

INTEREST IN THIS REPORT?

yangBenGet A Free Sample

baoJia Request For Quotation

OR

NEED A CUSTOMIZED REPORT?

DingZhiCustomized Report

biaoTi

WORLD WIDE OFFICE

application for samples

Request Sample

Custom reports

Pre-Order Enquiry

Add to Cart

Add to Cart

Buy Now

Buy Now